Different nAChR subtypes are considered as promising therapeutic targets for treatment of pain, cognitive impairment, depression, and other nervous diseases [56,57,58], neuromuscular disorders [59], inflammatory and skin diseases [60], and cancer therapy [36]. Here, CHRNA4 is linked to depressive symptom measurement.